Lv3
380 积分 2025-10-31 加入
Chemical discovery of a novel MD2/ADAM17 dual-target inhibitor as a potential therapeutic candidate for saturated fatty acid-induced myocardial inflammatory injury
1个月前
已完结
Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease
3个月前
已关闭
FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond
3个月前
已完结
NAFLD and NASH: etiology, targets and emerging therapies
3个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice
5个月前
已完结
皖公网安备34019202002308
